公开(公告)号：EP1237573B1

公开(公告)日：2013-08-14

申请号：EP00985439.9

申请日：2000-12-14

Applicant: NEOVACS

Inventor： ZAGURY, Daniel

IPC: A61K39/21 ,  C07K16/10 ,  A61K9/00 ,  A61K39/00 ,  A61K39/12

CPC classification number: C07K16/18 ,  A61K9/0043 ,  A61K39/12 ,  A61K39/21 ,  A61K2039/505 ,  A61K2039/53 ,  A61K2039/541 ,  A61K2039/542 ,  A61K2039/543 ,  A61K2039/545 ,  A61K2039/55505 ,  A61K2039/55544 ,  A61K2039/55566 ,  A61K2039/585 ,  C07K16/1036 ,  C07K16/1063 ,  C12N2740/16034 ,  C12N2740/16134 ,  C12N2740/16334

公开(公告)号：EP2147110B1

公开(公告)日：2011-11-02

申请号：EP08755984.5

申请日：2008-05-20

Applicant: The Gov. Of The USA As Represented By The Secretary Of The Dept. Of Health & Human Services ,  The Johns Hopkins University

Inventor： SWITZER, William, M. ,  HENEINE, Walid ,  FOLKS, Thomas, M. ,  WOLFE, Nathan, D. ,  BURKE, Donald, S. ,  SINTASATH, David, M.

IPC: C12N15/867 ,  C12N7/00 ,  C07K14/155 ,  C12Q1/68 ,  G01N33/50

CPC classification number: C07K14/005 ,  C07K16/1036 ,  C12N7/00 ,  C12N15/86 ,  C12N2740/14021 ,  C12N2740/14022 ,  C12N2740/14043 ,  G01N33/56983

Abstract: Disclosed are the simian T-cell lymphotropic virus type 3 subtype D (STLV-3 subtype D), isolated nucleic acid molecules encoding STLV-3 subtype D polypeptides, such as STLV-3 subtype D envelope, protease, polymerase, tax, rex, and capsid polypeptides, isolated polypeptides encoded by such nucleic acids. Methods are also disclosed for detecting STLV-3 subtype D, for example by detecting a STLV-3 subtype D nucleic acid or polypeptide in the sample. Accordingly, probes, primers, and antibodies for use in detecting STLV-3 subtype D nucleic acids or polypeptides are disclosed. Therapeutic compositions which included isolated nucleic acid molecules encoding a STLV-3 subtype D polypeptides or isolated polypeptides encoded by such nucleic acid molecules are also disclosed.

公开(公告)号：EP2160406A1

公开(公告)日：2010-03-10

申请号：EP08759960.1

申请日：2008-05-23

Applicant: AVIR GREEN HILLS BIOTECHNOLOGY RESEARCH DEVELOPMENT TRADE AG

Inventor： HUMER, Johannes ,  MAYER, Bernd ,  MUSTER, Thomas ,  WALTENBERGER, Andrea

IPC: C07K16/10 ,  C07K16/30 ,  A61K39/395 ,  A61P35/00 ,  G01N33/574 ,  G01N33/577

CPC classification number: C07K16/1036 ,  A61K2039/505 ,  C07K16/3053 ,  C07K2317/34 ,  C07K2317/73 ,  C07K2317/732

Abstract: The present invention provides antibodies, or fragments thereof, for isolating and/or identifying epitopes of an endogenous retrovirus, preferably of a melanoma associated endogenous retrovirus, and hybridoma cells producing said antibodies. The antibodies are useful especially for the treatment and diagnosis of cancer. Further, the present application covers diagnostic kits for the detection of cancer cells, especially of melanoma cells and methods for cancer diagnosis using said antibodies.

公开(公告)号：EP2001507A2

公开(公告)日：2008-12-17

申请号：EP06740999.5

申请日：2006-05-11

Applicant: AVIR GREEN HILLS BIOTECHNOLOGY RESEARCH DEVELOPMENT TRADE AG

Inventor： MAYER, Bernd ,  HUMER, Johannes ,  MUSTER, Thomas ,  WALTENBERGER, Andrea

IPC: A61K39/21 ,  A61K38/16

CPC classification number: A61K38/162 ,  A61K39/00 ,  C07K14/005 ,  C07K14/4748 ,  C07K16/1036 ,  C07K2317/34 ,  C12N2740/10022 ,  G01N33/5743 ,  G01N2333/15 ,  G01N2469/20

Abstract: The present invention provides antigenic polypeptides derived from the melanoma-associated endogenous retrovirus (MERV). These antigens are useful compounds for the detection of cancerous cells and melanoma-diagnosis as well as melanoma-prognosis. Furthermore these antigenic polypeptides of the present invention form the basis for anti-cancer vaccines.

公开(公告)号：EP1882032A2

公开(公告)日：2008-01-30

申请号：EP06749572.1

申请日：2006-04-07

Applicant: THE CLEVELAND CLINIC FOUNDATION ,  The Regents of the University of California

Inventor： SILVERMAN, Robert ,  KLEIN, Eric, A. ,  DERISI, Joseph ,  GANEM, Don ,  CASEY, Graham

IPC: C12N7/00

CPC classification number: C12N7/00 ,  A61K39/00 ,  C07K14/005 ,  C07K16/1036 ,  C12N9/22 ,  C12N2740/13021 ,  C12N2740/13022 ,  C12Q1/6886 ,  C12Q1/70 ,  C12Q1/701 ,  C12Q2600/136

Abstract: The present invention provides for isolated nucleic acid sequences encoding viruses; isolated polypeptides comprising amino acid sequences of the virus; vectors comprising the viral nucleic acid sequences; cells comprising the vectors; antibodies and antigen binding fragments thereof which have binding specificity for the virus; methods of detecting or screening for the virus (e.g., in an individual); methods of identifying agents that inhibit the virus; methods of inducing an immune response to the virus; methods of treating disease associated with the presence of XMRV in an individual (e.g., cancer such as prostate cancer); methods of detecting asymptomatic cancer (e.g., prostate cancer); methods of identifying an individual at risk for developing cancer (e.g., prostate cancer); and kits for detecting the virus.

公开(公告)号：EP0682703B1

公开(公告)日：2004-05-19

申请号：EP94907948.7

申请日：1994-02-02

Applicant: GENELABS TECHNOLOGIES, INC. ,  THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY

Inventor： HADLOCK, Kenneth G. ,  GOH, Chin-Joo ,  FONG, Steven K.H.

IPC: C12N15/12 ,  C12N15/62 ,  G01N33/566 ,  G01N33/577 ,  C12P21/08 ,  A61K39/21

CPC classification number: C07K7/06 ,  A61K38/00 ,  A61K39/00 ,  C07K14/005 ,  C07K16/1036 ,  C07K2319/00 ,  C07K2319/40 ,  C12N2740/14022

Abstract: Novel HTLV-I and HTLV-II peptides are disclosed for use in diagnostic assays for detecting and confirming HTLV-I and HTLV-II infection in human sera. The peptides are derived from analogous regions of HTLV-I and HTLV-II gp21 envelope protein, and are diagnostic of HTLV-I or HTLV-II infection. The invention also includes an assay kit and method for detecting, and discriminating between, HTLV-I and HTLV-II infection in humans.

公开(公告)号：EP0771356A4

公开(公告)日：1999-10-20

申请号：EP95927196

申请日：1995-07-14

Applicant: ALEXION PHARMA INC

Inventor： ROTHER RUSSELL P ,  ROLLINS SCOTT A ,  FODOR WILLIAM L ,  SPRINGHORN JEREMY P ,  SQUINTO STEPHEN P

IPC: C12N15/09 ,  A61K35/76 ,  C07K16/10 ,  C07K16/18 ,  C12N5/10 ,  C12N15/867 ,  C12P21/06 ,  A61K39/21 ,  C07H21/04 ,  C12P7/04 ,  C12P15/00

CPC classification number: C12N15/86 ,  C07K16/1036 ,  C07K16/18 ,  C12N2740/13043 ,  C12N2740/13051

公开(公告)号：EP0771356A1

公开(公告)日：1997-05-07

申请号：EP95927196.0

申请日：1995-07-14

Applicant: ALEXION PHARMACEUTICALS, INC.

Inventor： ROTHER, Russell P. ,  ROLLINS, Scott A. ,  FODOR, William L. ,  SPRINGHORN, Jeremy P. ,  SQUINTO, Stephen P.

IPC: C12N15 ,  A61K35 ,  C07K16 ,  C12N5

CPC classification number: C12N15/86 ,  C07K16/1036 ,  C07K16/18 ,  C12N2740/13043 ,  C12N2740/13051

Abstract: Methods and compositions are provided for facilitating gene therapy procedures involving the transduction of target cells with retroviral vector particles in the presence of complement containing body fluids. The reduction of levels of galactose alpha (1, 3) galactosyl epitopes on the retroviral vector particles and/or the blockade of antibody binding to such epitopes have been found to render the particles less sensitive to inactivation by complement mediated mechanisms, and to thus allow transduction in the presence of complement containing body fluids. Means are provided for obtaining such reductions.

公开(公告)号：EP0495008B1

公开(公告)日：1997-04-02

申请号：EP90917281.9

申请日：1990-10-01

Applicant: UNIVERSITY OF ARKANSAS

Inventor： WHITFILL, Craig, E. ,  FREDERICKSEN, Tommy, L. ,  TYCZKOWSKI, Julius, K. ,  THAXTON, James, Paul, Jr. ,  THOMA, John, A., Dr.

IPC: A61K39/42 ,  A61K39/12 ,  A61K39/00 ,  A61K35/14 ,  B65D35/14 ,  A01K33/00

CPC classification number: C07K16/1036 ,  A61K38/00 ,  A61K39/00 ,  A61K39/12 ,  A61K2039/505 ,  A61K2039/525 ,  A61K2039/552 ,  C07K16/08 ,  C07K16/081 ,  C12N2720/10034 ,  Y10S435/948

Abstract: A method of producing active immunity against a viral disease in an animal subject comprises administering to the subject a vaccine conjugate consisting essentially of a live virus and a neutralizing factor bound to the live virus. The neutralizing factor is selected from the group consisting of antibodies and antibody fragments. The live virus is one capable of producing disease in the subject, and the antibody or antibody fragment is one capable of neutralizing the live virus. Preferred subjects are birds, a preferred virus is Infectious Bursal Disease Virus, and a preferred route of administration to birds is by in ovo administration.

公开(公告)号：EP0755684A1

公开(公告)日：1997-01-29

申请号：EP96111909.6

申请日：1990-10-01

Applicant: UNIVERSITY OF ARKANSAS

Inventor： Whitfill, Craig E. ,  Fredericksen, Tommy L. ,  Tyczkowski, Julius K. ,  Thaxton, James Paul, Jr. ,  Thoma, John A., Dr.

IPC: A61K39/42 ,  A61K39/12 ,  A61K39/00 ,  A61K35/14 ,  B65D35/14

CPC classification number: C07K16/1036 ,  A61K38/00 ,  A61K39/00 ,  A61K39/12 ,  A61K2039/505 ,  A61K2039/525 ,  A61K2039/552 ,  C07K16/08 ,  C07K16/081 ,  C12N2720/10034 ,  Y10S435/948

Abstract: A method of producing active immunity against a viral disease in an animal subject comprises administering to the subject a vaccine conjugate consisting essentially of a live virus and a neutralizing factor bound to the live virus. The neutralizing factor is selected from the group consisting of antibodies and antibody fragments. The live virus is one capable of producing disease in the subject, and the antibody or antibody fragment is one capable of neutralizing the live virus.

Abstract translation: 在动物受试者中产生针对病毒性疾病的主动免疫的方法包括向受试者施用基本上由活病毒和与活病毒结合的中和因子组成的疫苗缀合物。 中和因子选自抗体和抗体片段。 活病毒是能够在受试者中产生疾病的活病毒，抗体或抗体片段是能够中和活病毒的物质。